MoonLake Securities Suits Intensify After Phase 3 Setback as Lead Plaintiff Deadline Nears
Investors are being urged by multiple firms to seek leadership in the SDNY case linked to the stock’s near 90% drop.
Overview
- Bleichmar Fonti & Auld says it has filed a securities class action against MoonLake and certain senior executives, citing Sections 10(b), 20(a) and Rule 10b-5, in Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612 (S.D.N.Y.).
- DJS Law Group and The Schall Law Firm are recruiting shareholders to move for lead-plaintiff status with a December 15, 2025 deadline.
- The proposed class covers investors who bought MoonLake securities from March 10, 2024 through September 29, 2025.
- Complaints allege MoonLake misled investors by claiming sonelokimab’s Nanobody-based advantages and superiority over monoclonal antibodies without proven clinical benefit.
- Plaintiffs tie the claims to MoonLake’s September 28, 2025 Phase 3 VELA results, including VELA-2 missing its primary endpoint, after which shares fell from $61.99 to $6.24; the litigation is in early stages and no class has been certified.